PrintThe Burrill Report
The Burrill Report (June 2, 2014): Big Pharma Continues to Dominate at ASCO (.MP3,11.37 Mb)
The American Society of Clinical Oncology’s ASCO 2014 Annual Meeting kicks off in Chicago May 30. Though this is a scientific meeting, it is closely watched by biotech investors looking for clinical results that can drive stock prices. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about how ASCO has become a Big Pharma story, how a new class of cancer immunotherapies continues to dominate the meeting, and what news to be watching that may be off the radar of investors.
May 30, 2014
http://www.burrillreport.com/article-big_pharma_continues_to_dominate_at_asco_.html
DRUG DEVELOPMENT
Big Pharma Continues to Dominate at ASCO
Podcast: June 2, 2014[Please login to post comments]
- Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More - Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin. Read More - New System for Classifying Cancer Could Change the Way Drugs Are Developed
Largest cancer genetic analysis reveals tumor subtype correlated to cell type rather than tissue type. Read More - Juno Therapeutics Fills Its Coffers with Another $134M
Funding for the biotech startup in hot CAR T-cell therapy space tops $300 million. Read More - Cerner Buys Siemens Health Services for $1.3B
Deal creates scale for future innovation, moving company beyond electronic medical records. Read More - Pharmas Tap Academia for Drug Discovery
Bristol-Myers teams with Allied Minds and Astellas teams with Cancer Research UK. Read More
